Verona Pharma PLC ADR (VRNA) - Total Assets
Based on the latest financial reports, Verona Pharma PLC ADR (VRNA) holds total assets worth $572.87 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore VRNA debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Verona Pharma PLC ADR - Total Assets Trend (2005–2024)
This chart illustrates how Verona Pharma PLC ADR's total assets have evolved over time, based on quarterly financial data. See net assets of Verona Pharma PLC ADR for net asset value and shareholders' equity analysis.
Verona Pharma PLC ADR - Asset Composition Analysis
Current Asset Composition (December 2024)
Verona Pharma PLC ADR's total assets of $572.87 Million consist of 95.6% current assets and 4.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 84.3% |
| Accounts Receivable | $37.26 Million | 7.9% |
| Inventory | $6.25 Million | 1.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $545.00K | 0.1% |
Asset Composition Trend (2005–2024)
This chart illustrates how Verona Pharma PLC ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Verona Pharma PLC ADR.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Verona Pharma PLC ADR's current assets represent 95.6% of total assets in 2024, a decrease from 100.0% in 2005.
- Cash Position: Cash and equivalents constituted 84.3% of total assets in 2024, down from 99.1% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 7.9% of total assets.
Verona Pharma PLC ADR Competitors by Total Assets
Key competitors of Verona Pharma PLC ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
Verona Pharma PLC ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.71 | 8.61 | 12.60 |
| Quick Ratio | 10.54 | 8.61 | 13.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $497.61 Million | $367.95 Million | $195.62 Million |
Verona Pharma PLC ADR - Advanced Valuation Insights
This section examines the relationship between Verona Pharma PLC ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 33.01 |
| Latest Market Cap to Assets Ratio | 15.41 |
| Asset Growth Rate (YoY) | 53.9% |
| Total Assets | $474.24 Million |
| Market Capitalization | $7.31 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Verona Pharma PLC ADR's assets at a significant premium (15.41x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Verona Pharma PLC ADR's assets grew by 53.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Verona Pharma PLC ADR (2005–2024)
The table below shows the annual total assets of Verona Pharma PLC ADR from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $474.24 Million | +53.91% |
| 2023-12-31 | $308.12 Million | +18.75% |
| 2022-12-31 | $259.47 Million | +39.06% |
| 2021-12-31 | $186.59 Million | -8.63% |
| 2020-12-31 | $204.21 Million | +245.06% |
| 2019-12-31 | $59.18 Million | -37.20% |
| 2018-12-31 | $94.23 Million | -22.10% |
| 2017-12-31 | $120.96 Million | +112.46% |
| 2016-12-31 | $56.93 Million | +419.34% |
| 2015-12-31 | $10.96 Million | -46.35% |
| 2014-12-31 | $20.43 Million | +384.57% |
| 2013-12-31 | $4.22 Million | -6.90% |
| 2012-12-31 | $4.53 Million | -30.66% |
| 2011-12-31 | $6.53 Million | +15.73% |
| 2010-12-31 | $5.64 Million | -26.81% |
| 2009-12-31 | $7.71 Million | +29.13% |
| 2008-12-31 | $5.97 Million | -1.11% |
| 2007-12-31 | $6.04 Million | -22.25% |
| 2006-12-31 | $7.77 Million | +355.45% |
| 2005-12-31 | $1.71 Million | -- |
About Verona Pharma PLC ADR
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pu… Read more